Preventing venous thromboembolism following orthopedic surgery in the United States: Impact of special populations on clinical outcomes

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 6, 2011, Pages 640-650

  Deitelzweig, Steven B ^a   Lin, Jay ^b   Lin, Grace ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Bruce Wong and Associates Inc   (United States)

^c HCO Research   (United States)

Author keywords

anticoagulant regimens; orthopedic surgery; venous thromboembolism

Indexed keywords

CYTOCHROME P450 3A4; WARFARIN;

ARTICLE; BLEEDING; FEMALE; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; KIDNEY FAILURE; KNEE ARTHROPLASTY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

AGED; FEMALE; HUMANS; MALE; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84863164809     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611404215     Document Type: Article

References (22)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133 (6 suppl). 381S - 453S (Pubitemid 351894916)
2. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004 ; 2 (9). 1573-1580 (Pubitemid 40186173)
3. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006 ; 4 (1). 121-128
4. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin. 2006 ; 22 (3). 471-481
5. Lovenox (enoxaparin sodium injection). Prescribing information, December 2009. sanofi-aventis U.S., Bridgewater, NJ. http://products.sanofi-aventis.us/ lovenox/lovenox.pdf. Accessed September, 2010.
6. Pradaxa (dabigatran etexilate). Summary of product characteristics, March 2009. Boehringer Ingelheim International GmbH, Germany. http://www.pradaxa.com/ Include/media/pdf/Pradaxa-SPC-EMEA.pdf. Accessed September, 2010.
7. Xarelto (rivaroxaban). Summary of product characteristics, May 2009. Bayer Schering Pharma, Germany. http://xarelto.com/html/downloads/Xarelto- Summary-of-Product-Characteristics-May2009.pdf. Accessed Septmeber, 2010.
8. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004 ; 164 (20). 2260-2265 (Pubitemid 39456437)
9. Clark NP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008 ; 123 (suppl 1). S58 - S61
10. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133 (6 suppl). 160S - 198S (Pubitemid 351892967)
11. Hawkins K, Mittapally R, Chang J, Nahum GG, Gricar J. Burden of illness of hypertension among women using menopausal hormone therapy: a US perspective. Curr Med Res Opin. 2010 ; 26 (12). 2823-2832
12. Cohen AT, Tapson VF, Bergmann J-F, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008 ; 371 (9610). 387-394 (Pubitemid 351173321)
13. Amin AN, Stemkowski S, Lin J, Yang G. Inpatient thromboprophylaxis use in U.S. hospitals: adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients. J Hosp Med. 2009 ; 4 (8). E15 - E21
14. Deitelzweig SB, Lin J, Hussein M, Battleman D. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?. J Thromb Thrombolysis. 2010 ; 30 (1). 55-66
15. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007 ; 64 (1). 69-76 (Pubitemid 46395711)
16. Amin A, Spyropoulos AC, Dobesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis. 2010 ; 29 (3). 326-339
17. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis. 2009 ; 28 (4). 458-464
18. Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost. 2007 ; 5 (5). 937-941 (Pubitemid 46691722)
19. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009 ; 123 (3). 488-497
20. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg. 2009 ; 250 (2). 219-228
21. Eikelboom JW, Weitz JI. A replacement for warfarin: the search continues. Circulation. 2007 ; 116 (2). 131-133 (Pubitemid 47057517)
22. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother. 1998 ; 32 (12). 1299-1302 (Pubitemid 29013352)